Categories Technology

Alibaba to combine food delivery services into one business

China’s food-to-flight services platform, Meituan-Dianping has been witnessing fast growth posing threat to larger rivals such as Alibaba (BABA). And Alibaba is now hoping to combine its food delivery services into one business as well as raise funds for it, in a move to tackle this new threat.

The on-demand service, which is a huge business in China today, is seeing a growing rivalry between  Meituan-Dianping, which is backed by Chinese Internet services giant Tencent Holdings Group Ltd,  and Ele.Me, the food delivery app Alibaba acquired for $9.5 billion this year.

Alibaba is contemplating on combining its food delivery platform Ele.me and food and lifestyle services firm Koubei into one business, according to Reuters. Alibaba also plans to raise close to $3 billion to $5 billion for the merged entity, which is valued at $25 million. SoftBank Group Corp.’s Vision Fund is said to lead the funding.

RELATED: Alibaba’s Ele.Me to deliver food using drones in China

Despite their popularity, both Ele.me and Meituan are running into huge losses, mainly due to the heavy discounts offered on food.

Food-delivery business in China is booming

According to a report by Meituan Waimai, a food delivery firm, there was a 23% rise in the online food delivery to 204.6 billion yuan (about $31.9 billion) in 2017. And nearly 300 million users have ordered food using online services.

RELATED: Alibaba digests Chinese food delivery platform Ele.me

Due to this, both the rival companies are now pumping money into this business and are working towards expanding their offerings.  Currently, they offer a wide range of services right from food delivery to restaurant reviews to groceries.

In fact, Meituan-Dianping has also forayed into the bike-sharing sector by acquiring Mobike for $3.7 billion. Mobike’s main rival is Ofo, backed the Alibaba.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top